Abiopharma

🔍 DONDERO JAMES D (Director)

Company: NexPoint Real Estate Finance, Inc. (NREF)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Acquired 36,830 shares of Common Stock (Direct)
  Date: 2026-04-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 458,966.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 33,284 shares of Common Stock (Direct)
  Date: 2026-04-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 492,250.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 5,694,671.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 3,649,759.00 | Footnotes: F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 327,286.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,800.00 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-02 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 248,996.00 | Footnotes: F2, F7
• Acquired 197,789 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 197,789.00 | transaction_form_type: 4 | Footnotes: F1, F8, F8
• Sold 36,830 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 110,489.00 | transaction_form_type: 4 | Footnotes: F1, F9, F9
• Sold 33,284 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 33,283.00 | transaction_form_type: 4 | Footnotes: F1, F10, F10

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of common stock of NexPoint Real Estate Finance, Inc. (the "Issuer").
• F2: Includes shares acquired under the dividend reinvestment plan of the Issuer.
• F3: 1,322,385 shares are held by Highland Global Allocation Fund and 4,372,286 shares are held by Highland Opportunities and Income Fund. These entities are managed by NexPoint Asset Management, L.P. ("NexPoint Asset Management"). Mr. Dondero is the sole stockholder and director of Strand Advisors XVI, Inc., NexPoint Asset Management's general partner, and may be deemed to be an indirect beneficial owner of securities held by NexPoint Asset Management. Mr. Dondero disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F4: 2,952,273 shares are held by NexPoint Diversified Real Estate Trust Operating Partnership, L.P., 281,817 shares are held by NexPoint Real Estate Strategies Fund and 415,669 shares are held by NexPoint Capital, Inc. These entities are managed or advised, directly or indirectly, by NexPoint Advisors, L.P. ("NP"). Mr. Dondero is the sole member of NP's general partner, and may be deemed to be an indirect beneficial owner of securities held by NP. Mr. Dondero disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F5: 95,207 shares are held by a company which is an indirect wholly owned subsidiary of a trust of which Mr. Dondero is the beneficiary. The remaining shares of common stock are held directly by the trust. Mr. Dondero disclaims beneficial ownership of the shares held directly or indirectly by the trust except to the extent of his pecuniary interest therein.
• F6: These shares are held by a limited liability company in which the trust referenced in footnote 5 to this Form 4 owns a majority interest. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
• F7: These shares are held by a trust. Mr. Dondero disclaims beneficial ownership of such shares.
• F8: On April 2, 2026, the reporting person was granted 197,789 restricted stock units. The restricted stock units vest one-fourth on April 2, 2027, one-fourth on February 15, 2028, one-fourth on February 15, 2029 and one-fourth on February 15, 2030. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.
• F9: On April 3, 2025, the reporting person was granted 147,319 restricted stock units. The restricted stock units vested one-fourth on April 3, 2026 and will vest one-fourth on February 15, 2027, one-fourth on February 15, 2028 and one-fourth on February 15, 2029. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.
• F10: On April 4, 2023, the reporting person was granted 133,135 restricted stock units. The restricted stock units vested one-fourth on April 4, 2024, one-fourth on April 4, 2025 and one-fourth on April 4, 2026 and will vest one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.